Molecular basis for persistence of botulinum neurotoxin: The role of intracellular protein degradation pathways

Molecular Aspects of Botulinum Neurotoxin

Volumn , Issue , 2014, Pages 191-205

  Tsai, Yien Che ^c   Moller, Brian E ^d   Adler, Michael ^d   Oyler, George A ^a,b  

^a SYNAPTIC RESEARCH LLC   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

Bioterrorism; Botulinum neurotoxin; Deubiquitination; Persistence; Ubiquitination

Indexed keywords

EID: 85028293475     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-9454-6_9     Document Type: Chapter

References (60)

1. Adler M, Macdonald DA, Sellin LC, Parker GW (1996) Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin. Toxicon 34:237-249
2. Adler M, Keller JE, Sheridan RE, Deshpande SS (2001) Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon 39:233-243
3. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059-1070
4. Baldwin MR, Barbieri JT (2009) Association of botulinum neurotoxins with synaptic vesicle protein complexes. Toxicon 54:570-574
5. Binz T, Blasi J, Yamasaki S, Baumeister A, Link E, Sudhof TC, Jahn R, Niemann H (1994) Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem 269:1617-1620
6. Brin MF (2009) Basic and clinical aspects of BOTOX. Toxicon 54:676-682
7. Chen S, Barbieri JT (2011) Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25. J Biol Chem 286:15067-15072
8. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO (1999) Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 96:3200-3205
9. Dolly JO, Ashton AC, McInnes C, Wadsworth JD, Poulain B, Tauc L, Shone CC, Melling J (1990) Clues to the multi-phasic inhibitory action of botulinum neurotoxins on release of transmitters. J Physiol (Paris) 84:237-246
10. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312:592-596
11. Dong M, Tepp WH, Liu H, Johnson EA, Chapman ER (2007) Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons. J Cell Biol 179:1511-1522
12. Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C (1998) Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256:135-138
13. Erdal E, Bartels F, Binscheck T, Erdmann G, Frevert J, Kistner A, Weller U, Wever J, Bigalke H (1995) Processing of tetanus and botulinum A neurotoxins in isolated chromaffin cells Naunyn Schmiedebergs. Arch Pharmacol 351:67-78
14. Fernandez-Salas E, Ho H, Garay P, Steward LE, Aoki KR (2004a) Is the light chain subcellular localization an important factor in botulinum toxin duration of action? Mov Disord 19(Suppl 8):S23-S34
15. Fernandez-Salas E, Steward LE, Ho H, Garay PE, Sun SW, Gilmore MA, Ordas JV, Wang J, Francis J, Aoki KR (2004b) Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc Natl Acad Sci U S A 101:3208-3213
16. Fischer A, Sambashivan S, Brunger AT, Montal M (2012) Beltless translocation domain of botulinum neurotoxin A embodies a minimum ion-conductive channel. J Biol Chem 287:1657-1661
17. Foran PG, Mohammed N, Lisk GO, Nagwaney S, Lawrence GW, Johnson E, Smith L, Aoki KR, Dolly JO (2003) Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, F compared with the long lasting type A Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem 278:1363-1371
18. Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, Pavlin JA, Christopher GW, Eitzen EM Jr (1997) Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278:399-411
19. Gu S, Rumpel S, Zhou J, Strotmeier J, Bigalke H, Perry K, Shoemaker CB, Rummel A, Jin R (2012) Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 335:977-981
20. Habermann E, Dreyer F (1986) Clostridial neurotoxins: handling and action at the cellular and molecular level. Curr Top Microbiol Immunol 129:93-179
21. Hatakeyama S, Watanabe M, Fujii Y, Nakayama KI (2005) Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation. Cancer Res 65:7874-7879
22. Hochstrasser M (1996) Ubiquitin-dependent protein degradation. Annu Rev Genet 30:405-439
23. Jankovic J, Brin MF (1997) Botulinum toxin: historical perspective and potential new indications. Muscle Nerve Suppl 6:S129-S145
24. Jurasinski CV, Lieth E, Do Dang AN, Schengrund CL (2001) Correlation of cleavage of SNAP-25 with muscle function in a rat model of botulinum neurotoxin type A induced paralysis. Toxicon 39:1309-1315
25. Kalandakanond S, Coffield JA (2001) Cleavage of intracellular substrates of botulinum toxins A, C, and D in a mammalian target tissue. J Pharmacol Exp Thera 296:749-755
26. Keller JE (2006) Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience 139:629-637
27. Keller JE, Neale EA, Oyler G, Adler M (1999) Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett 456:137-142
28. Klionsky DJ (2005) The molecular machinery of autophagy: unanswered questions. J Cell Sci 118:7-18
29. Kuo CL, Oyler GA, Shoemaker CB (2011) Accelerated neuronal cell recovery from botulinum neurotoxin intoxication by targeted ubiquitination. PLoS One 6:e20352
30. Lebeda FJ, Adler M, Erickson K, Chushak Y (2008) Onset dynamics of type A botulinum neurotoxin-induced paralysis. J Pharmacokinet Pharmacodyn 35:251-267
31. Lipkowitz S, Weissman AM (2011) RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer 11:629-643
32. Lundh H, Leander S, Thesleff S (1977) Antagonism of the paralysis produced by botulinum toxin in the rat The effects of tetraethylammonium, guanidine and 4-aminopyridine. J Neurol Sci 32:29-43
33. Meunier FA, Schiavo G, Molgo J (2002) Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris 96:105-113
34. Meunier FA, Lisk G, Sesardic D, Dolly JO (2003) Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol Cell Neurosci 22:454-466
35. Morbiato L, Carli L, Johnson EA, Montecucco C, Molgó J, Rossetto O (2007) Neuromuscular paralysis and recovery in mice injected with botulinum neurotoxins A and C. Eur J Neurosci 25:2697-2704
36. Oyake D, Nishikawa H, Koizuka I, Fukuda M, Ohta T (2002) Targeted substrate degradation by an engineered double RING ubiquitin ligase. Biochem Biophys Res Commun 295:370-375
37. Ravichandran E, Gong Y, Al-Saleem FH, Ancharski DM, Joshi SG, Simpson LL (2006) An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 318:1343-1351
38. Rogozhin AA, Pang KK, Bukharaeva E, Young C, Slater CR (2008) Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin A. J Physiol 586:3163-3182
39. Rubinsztein DC (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443:780-786
40. Schantz EJ, Johnson EA (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 56:80-99
41. Schiavo G, Santucci A, Dasgupta BR, Mehta PP, Jontes J, Benfenati F, Wilson MC, Montecucco C (1993) Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOHterminal peptide bonds. FEBS Lett 335:99-103
42. Schiavo G, Shone CC, Bennett MK, Scheller RH, Montecucco C (1995) Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxins. J Biol Chem 270:10566-10570
43. Scott AB, Magoon EH, McNeer KW, Stager DR (1989) Botulinum treatment of strabismus in children. Trans Am Ophthalmol Soc 87:174-180
44. Shapiro RL, Hatheway C, Swerdlow DL (1998) Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med 129:221-228
45. Siegel LS, Johnson-Winegar AD, Sellin LC (1986) Effect of 3,4-diaminopyridine on the survival of mice injected with botulinum neurotoxin type A, B, E, or F. Toxicol Appl Pharmacol 84:255-263
46. Simpson LL (1981) The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 33:155-188
47. Simpson LL (1986) Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol 26:427-453
48. Simpson LL (2004) Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 44:167-193
49. Sobel J (2005) Botulism. Clin Infect Dis 41:1167-1173
50. Souayah N, Karim H, Kamin SS, McArdle J, Marcus S (2006) Severe botulism after focal injection of botulinum toxin. Neurology 67:1855-1856
51. Tsai YC, Maditz R, Kuo CL, Fishman PS, Shoemaker CB, Oyler GA, Weissman AM (2010) Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci U S A 107:16554-16559
52. Vaidyanathan VV, Yoshino K, Jahnz M, Dorries C, Bade S, Nauenburg S, Niemann H, Binz T (1999) Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage. J Neurochem 72:327-337
53. Veit M, Sollner TH, Rothman JE (1996) Multiple palmitoylation of synaptotagmin and the t-SNARE SNAP-25. FEBS Lett 385:119-123
54. Wang J, Zurawski TH, Meng J, Lawrence G, Olango WM, Finn DP, Wheeler L, Dolly JO (2011) A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis:transfer of longevity to a novel potential therapeutic. J Biol Chem 286:6375-6385
55. Washbourne P, Pellizzari R, Rossetto O, Bortoletto N, Tugnoli V, De Grandis D, Eleopra R, Montecucco C (1998) On the action of botulinum neurotoxins A and E at cholinergic terminals. J Physiol Paris 92:135-139
56. Wein LM, Liu Y (2005) Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc Natl Acad Sci U S A 102:9984-9989
57. Weissman AM (2001) Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2:169-178
58. Yi JJ, Ehlers MD (2007) Emerging roles for ubiquitin and protein degradation in neuronal function. Pharmacol Rev 59:14-39
59. Zhou P (2005) Targeted protein degradation. Curr Opin Chem Biol 9:51-55
60. Zhou P, Bogacki R, McReynolds L, Howley PM (2000) Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol Cell 6:751-756